Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 443651 in Healthy Male Volunteers in a Partially Randomised, Single Blind, Placebo-controlled Trial
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2017
At a glance
- Drugs BI 443651 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 27 Jun 2016 Status changed from recruiting to completed.
- 04 Apr 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 15 Mar 2016 New trial record